Products
Online Inquiry
GDC0084
Cat. No.:
0225LY-0634
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
GDC0084 is a PI3K inhibitor with prospective antineoplastic use that specifically blocks the PI3K/AKT signaling pathway to limit the survival and growth of tumor cells.
Synonym:
GDC-0084; 1382979-44-3; Paxalisib; 5-(6,6-dimethyl-4-morpholin-4-yl-8,9-dihydropurino[8,9-c][1,4]oxazin-2-yl)pyrimidin-2-amine; 5-(6,6-Dimethyl-4-morpholino-8,9-dihydro-6H-[1,4]oxazino[4,3-e]purin-2-yl)pyrimidin-2-amine; 2-Pyrimidinamine, 5-[8,9-dihydro-6,6-dimethyl-4-(4-morpholinyl)-6H-[1,4]oxazino[4,3-e]purin-2-yl]-; 5-(6,6-Dimethyl-4-morpholino-8,9-dihydro-6H-[1,4]oxazino[3,4-e]purin-2-yl)pyrimidin-2-amine; 5-(6,6-Dimethyl-4-(4-morpholinyl)-8,9-dihydro-6H-(1,4)oxazino(4,3-e)purin-2-yl)-2-pyrimidinamine; 5-[8,9-dihydro-6,6-dimethyl-4-(4-morpholinyl)-6H-[1,4]oxazino[4,3-e]purin-2-yl]-2-pyrimidinamine
CAS No.:
1382979-44-3
Compound CID:
57384863
Formula:
C18H22N8O2
Formula Weight:
382.42
Specification
Targets&IC50:
PI3Kβ: 46 nM(Ki app); PI3Kα: 2 nM(Ki app); PI3Kδ: 3 nM(Ki app); mTOR: 70 nM(Ki app); PI3Kγ: 10 nM(Ki app)
Relative Density:
1.60 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
GDC0084 can be used in neuro-oncology to study the inhibition of PI3K/mTOR signaling in brain-localized tumors.
Library Information
Target:
mTOR; PI3K
Receptor:
mTOR; PI3Kα; PI3Kβ; PI3Kγ; PI3Kδ
Pathways:
PI3K/Akt/mTOR signaling
Plate Number:
AOCL-9
Plate Location:
b10
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
3.83 mg/mL; 10.02 mM
Water Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
Ethanol Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
ALogP:
0.588
HBA_Count:
7
HBD_Count:
1
Rotatable Bond:
2
